08:00 Thu 22 Aug 2019
IXICO plc - Directorate Change
22nd August 2019
("IXICO" or the "Company")
Directorate changes
As anticipated,
Following the directorate changes the Company will have two executive directors and three independent non-executive directors.
Pursuant to Schedule 2 (g) of the AIM Rules for Companies,
Current |
Previous |
|
None |
There is no further information required to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.
For further information please contact:
|
+44 (0) 20 3763 7498 |
|
|
Cenkos Securities PLC (Nominated adviser and sole broker) |
+44 (0) 20 7397 8900 |
|
|
Michael F Johnson / |
|
|
+44 (0) 203 950 9144 |
Mary Clark / |
|
|
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE